Sunmnary A reliable test that detects malignancy and indicates response to therapy is needed. Frequencypulsed electron-capture gas-liquid chromatography (FPEC-GLC), a selective analytical technique that is sensitive to 15 fmol quantities of metabolites, was used to analyse derivatised acidic chloroform extracts of sera from patients with biopsy-proven cancer, non-malignant infectious and non-infectious disease, and healthy controls. Two peaks designated PI and Pl0, not found in serum from healthy controls (n = 7) or patients with non-malignant disease (n = 85), were detected in biopsy-proven samples (n = 52) from cancer patients. PI and Pl0 were later shown by chemical and mass spectral studies to be carboxylic acids. When one or both of these peaks were detected in the sera of non-treated patients they were always associated with malignancy. In patients responding to therapy, a reduction or disappearance of these peaks was observed. Further, it was noted that P10 persisted or increased in sera of patients with progressive cancer not responding to therapy. We conclude that this test has potential in diagnosis and for following the response of the disease to therapy.
Approximately 25% of all deaths in the USA are the result of cancer (Sondik, 1988) . Because this may be due in part to the lack of early detection and treatment, attempts have been made to develop tests useful for the early diagnosis of cancer. These include the detection of carcinoembryonic antigen, alpha-fetoprotein and tumour-associated antigens and nuclear magnetic resonance. Unfortunately, these tests have unacceptably low sensitivity and specificity for the diagnosis of cancer, and their primary use is as markers of disease activity (Garrett & Kurtgis, 1985; Engan et al., 1990; Sell, 1990) .
Frequency-pulsed electron-capture gas -liquid chromatography (FPEC-GLC) of various body fluids has been used to detect metabolites associated with infectious and noninfectious diseases (Brooks et al., 1972 (Brooks et al., , 1986 (Brooks et al., , 1987 (Brooks et al., , 1990 Daneshavar et al., 1988) . In these studies, diagnostic FPEC-GLC profiles were characterised by comparing specimens from patients with disease and healthy controls. During our studies of cerebrospinal fluid (CSF) and serum from patients with suspected tuberculous meningitis, we received several specimens from persons who were later determined to have cancer, identified infection or characterised non-infectious disease. After observing several reproducible FPEC-GLC profiles from specimens of patients who had a final diagnosis of cancer and then enhancing the peaks of certain metabolites repeatedly associated with the disease, we began prospectively testing sera of patients with cancer to determine the ability of FPEC-GLC to detect cancer-associated metabolites. Hampton, Virginia, and Halifax, Nova Scotia. The histological type of tumour was determined by microscopic examination of biopsied tissue by pathologists at the participating institutions. Specimens were obtained from patients before, during or after therapy (surgery, radiation or chemotherapy). The impact of therapy was reported by the patient's physician as effective, partially effective or ineffective; no uniform objective criteria were applied for this classification. FPEC-GLC profiles also were determined for serum and CSF specimens of 94 controls who either were healthy or had a variety of non-neoplastic conditions. The latter specimens were originally sent for evaluation of possible tuberculous meningitis.
Collection of blood Blood (1O ml) was collected from patients, and allowed to clot and retract at room temperature. Serum was separated from the clot by centrifugation at 2,000 g for 5 min and then transferred with sterile Pasteur pipettes to a 15 ml conical screw-capped centrifuge tube (Corning Glass Company, NY, USA). The sample was centrifuged again at 2,000 g for 5 min to remove residual red blood cells. The serum supernatant was transferred to sterile tubes for storage at -70°C without any chemical additives or preservatives. All samples were shipped to the Centers for Disease Control Laboratory on dry ice to prevent thawing before analysis.
Frequency-pulsed electron-capture gas-liquid chromatography Trichloroethanol (TCE) esters were prepared by the method described by Brooks et al. (1990) using an internal standard (C) and C18 reversed-phase column clean-up. The sample was placed in 200 y1 of a final solvent of 50% (v/v) xyleneethanol, and the sample was transferred to a Teflon-lined screw-cap glass inserted vial (National Scientific, Lawrenceville, GA, USA) and 2 1l was injected by autosampler. The samples were analysed by FPEC-GLC as previously described (Brooks et al., 1990) . Specimens included in this study were coded, and the FPEC-GLC chromatograms were grouped blinded to diagnosis (Table I) . ass spectral analysis For mass spectral (MS) analysis of cancer-associated metabolites, pentafluorobenzylbromide (PFB) derivatives were prepared from acidic chloroform extracts (Daneshvar & Brooks, 1988) of sera from cancer patients shown by previous FPEC-GLC analysis to contain large quantities of these metabolites. The first MS study used a Finnigan TSQ 46 gas chromatography-mass spectrometry data system equipped with a splitless injector and an OV-1 fused-silica, large-bore, bonded-phase capillary column, as described above for FPEC-GLC analysis. The carrier gas was helium at a flow rate of 1 ml min-'. The derivatised sample (4 ttl) was injected into the instrument and kept at 90°C for 3 min. The injector was then maintained at 180°C, vented and the instrument was programmed for a linear temperature increase of 6°C min-' to 275°C and was kept isothermal at this temperature for 26 min. Electron impact spectra and positive and negative chemical ionisation spectra were obtained. The reagent gas used for CI was methane (Matheson, Suwanee, GA, USA).
For the second MS study, we used gas chromatography (GC)-MS and MS-MS. Spectra were acquired using a Finnigan TSQ-70 instrument equipped with a HewlettPackard 5880 GC (Atlanta, GA, USA). The 5880 GC was equipped with a 30 m x 0.25 mm ID fused-silica column coated with a 0.25 ytm film of DB-1 (J & W Scientific, Folsom, CA, USA). For analysis, the injector and transfer temperatures were maintained at 300°C while the column temperature was held isothermal at 90°C for 4 min, then programmed for a linear increase of 4°C min-' to 275°C and held at this temperature for 30 min. The column was coupled directly into the electron or chemical ionisation source, which was maintained at 160°C. Spectra were recorded over a range of 50-700 a.m.u. s-using the Finnigan ICIS data system (Houston, TX, USA). Daughter spectra were obtained by mass selecting the appropriate ion in the first quadrupole, dissociating it up on collision with millitorr argon at energies of 20-30 eV in the second quadruple, and scanning the third quadrupole. Background spectra were subtracted from the spectra of interest.
Statistical methods
Associations between FPEC-GLC peaks 1 and 10 and type or site of tumour or treatment efficacy were determined in 2 x 2 tables using the chi-square test; when one or more cells had an expected value of less than 5, the two-tailed Fisher exact test was used. The association between increasing effectiveness of therapy and the presence of these peaks was determined using the chi-square test for linear trend. The height of Plo was associated with treatment effectiveness using the Kruskal-Wallis test for non-normally distributed data.
Results
A total of 52 patients with malignancy were studied. Primary tumour sites and histological types are shown in Table I . The most common primary sites were breast (22), colon (11) and lung (9). The most common histological type was adenocarcinoma (30). Patients ranged in age from 2 to 75 years (mean 55). Ten patients had received no treatment; for those who had received therapy, treatment was classified as ineffective for 10, partially effective for 17 and effective for 14 (Table I) . A total of 94 patients were studied, which included healthy subjects, patients characterised as having non-malignant diseases and patients with various characterised infectious diseases. The patients with infectious diseases were also examined as controls.
Identification of cancer-associated metabolites Four FPEC-GLC patterns were observed among the 52 specimens from cancer patients (Table I and Figures 1-4) . These RPC column as seen by comparing computer-expanded portions of FPEC-GLC patterns (Figure la and b) . P1 was not found in the enhanced specimen from healthy controls (Figure lc) . It possessed unusual chromatographic characteristics in that the TCE ester did not elute on polar OV-225 or on the moderately polar OV-1701 capillary columns, and the ester slowly decomposed after standing for a month at 4°C. P1 was extractable with chloroform under acidic but not basic conditions. It did not react with heptafluorobutyric anhydride either before or after esterification with TCE or PFB, and the TCE ester did not react with hydrogen in the presence of a platinum catalyst; therefore, PI was determined to be a saturated, short-chain, carboxylic acid without free amine or hydroxyl groups.
MS analysis of TCE-derivatised samples that contained large amounts (five times full scale) of P1 by FPEC-GLC analysis was attempted on two occasions without obtaining meaningful spectra. We next used MS to analyse PFBderivatised acidic chloroform extracts of sera taken from the same patients as the sera initially tested as TCE derivatives, and we were able to obtain mass spectra on PI. The positive methane chemical ionisation mass spectrum of P1 ( Figure Sa) showed the protonated molecule at m/z 271 and fragments at m/z 243, 225 and 181 (base peak). The m/z 181 fragment is also the base peak in the electron ionisation mass spectrum of PI, which includes a subsequent hydrogen fluoride (HF) loss fragnent at m/z 161 but no molecular ion. The molecular weight is confirmed from its negative methane chemical ionisation mass spectrum whose base peak was the m/z 89 fragment formed from dissociative electron attachment, resulting in the loss of the PFB derivative. Mass selection of the m/z 89 anion with subsequent collisional activation and daughter ion analysis indicated two fragments at m/z 43 and 45. From the spectra we concluded that P1 was a monocarboxylic acid and that the underivatised acid had a molecular derivative is 500. Together, these data indicate a molecular weight of 240 for the underivatised Pl0. The derivatised compound contains two TCE groups or two PFB groups, indicating that it is a dicarboxylic acid. The fragmentation pattern of the electron impact spectra (Figure 6 ) indicates a highly oxygenated compound with a very tentative structure presented (Figure 7 ). Evidence has been presented (McDonagh et al., 1992 ) that monocytes and macrophages, in response to malignant tumours, release components that affect lipid metabolism and perioxidation was presented as one mechanism. Pl0, like Pi, was not detected on the OV-225 polar column. In addition to peaks 1 and 10, several other peaks not found in controls were found in specimens from some cancer patients (Figure 4, peaks 3, 4, 7, 8 and 9 ). These substances were not always found in specimens that contain Plo and they were usually seen in patients seriously ill with cancer. They have not been characterised further. (Bates & Lono, 1987) . Some of the markers extensively investigated for their value include carcinoembryonic antigen, alpha-fetoprotein, human chorionic gonadotrophic hormone and prostatic acid phosphatase. These markers most often are measured by radioimmunoassays (RIAs). While the assays detect nanogram levels of the markers, they lack the sensitivity and specificity to serve as screening tools for the early detection of cancer and have been most effective in disease management or for following the progression of previously diagnosed cancer.
More recently, the analysis of human plasma by nuclear magnetic resonance (NMR) was used to discriminate between healthy controls and cancer patients (Fossel et al., 1986) . However, further studies have indicated that this method lacks the specificity to serve as a test for the early diagnosis of cancer (Okunieff et al., 1990; Shulman, 1990 Peaks 1 and 10 cannot be absolutely quantitated on a molar basis by FLPEC-GLC without positive identification and comparison of the detector response to the actual compound because the response of the detector depends on the electron-absorbing characteristics of the derivatised compound; however, observations on peak concentration made from peak height and area obtained by comparison with an internal standard are valid. Although our study suggests that detection of specific peaks in specimens examined by FPEC-GLC was both sensitive and specific for patients with malignancy, the principal value of this procedure depends on its ability to detect malignancies early (before clinical signs or other diagnostic tests) or its ability to be used as a marker for the efficacy of therapy. Some data suggest that the presence and concentration of these metabolites vary with the success of therapy; however, the effect of therapy was not well quantified and serial specimens obtained during therapy from individual patients were not available. Prospective longitudinal studies of patients undergoing therapy are needed in order to validate this test's utility in monitoring the impact of treatment. Determining whether this procedure is useful as a diagnostic test might be accomplished by testing patients in groups at high risk for developing a malignancy and prospectively following patients with positive and negative test results for the development of cancer detected by standard methods.
FPEC-GLC tests on clinical samples of body fluids for tuberculous meningitis have been reported (Brooks et al., 1990) , and are presently being conducted by this laboratory. Further, the derivatisation technique used in the study has been refined and made practical, highly reproducible and reliable. Samples can be automatically injected into the gas chromatograph, and computers are available that expedite the handling of the data.
Results from this study indicate that FPEC-GLC may eventually offer the physician a means to screen and diagnose malignancies and to determine the effectiveness of cancer therapy.
